Mechanisms of cancer induction by tobacco-specific NNK and NNN

Cancers

Volumn 6, Issue 2, 2014, Pages 1138-1156

  Xue, Jiaping ^a   Yang, Suping ^b   Seng, Seyha ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Nitrosamines; Tobacco

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARCINOGEN; NITROSONORNICOTINE; TOBACCO SMOKE;

CANCER GROWTH; CARCINOGEN DNA INTERACTION; CARCINOGENESIS; CAUSAL ATTRIBUTION; CHEMICAL STRUCTURE; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; EPIDEMIC; EXCISION REPAIR; GENOTOXICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; PASSIVE SMOKING; REVIEW; SIGNAL TRANSDUCTION; SMOKELESS TOBACCO; TOBACCO; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

EID: 84901218529     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6021138     Document Type: Review

References (115)

1. Danaei, G.; Vander Hoorn, S.; Lopez, A.D.; Murray, C.J.; Ezzati, M.; Comparative Risk Assessment Collaborating Group. Causes of cancer in the world: Comparative risk assessment of nine behavioral and environmental risk factors. Lancet 2005, 366, 1784-1793.
2. World Health Organization. Reducing risks, promoting healthy life. In The World Health Report; WHO: Geneva, Switzerland, 2002.
3. Hecht, S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 2003, 3, 733-744.
4. Jatoi, I.; Cummings, K.M.; Cazap, E. Global tobacco problem getting worse, not better. J. Oncol. Pract. 2009, 5, 21-23.
5. US Department of Health and Human Services. Preventing Tobacco Use among Youth and Young Adults: A Report of the Surgeon General; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2012.
6. World Health Organization. Global Cancer Rates Could Increase by 50% to 15 Million by 2020. Available online: http://www.who.int/mediacentre/news/releases/2003/pr27/en/ (accessed on 5 January 2014).
7. Hukkanen, J.; Jacob, P., 3rd; Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 2005, 57, 79-115.
8. Warren, G.W.; Singh, A.K. Nicotine and lung cancer. J. Carcinog. 2013, doi:10.4103/1477-3163.106680.
9. Doll, R.; Peto, R. The Causes of Cancer; Oxford Press: New York, NY, USA, 1981; pp. 1-144.
10. US Department of Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General; Centers for Disease Control and Prevention: Atlanta, GA, USA, 1989.
11. Secretan, B.; Straif, K.; Baan, R.; Grosse, Y.; El Ghissassi, F.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L. et al. A review of human carcinogens-Part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009, 10, 1033-1034.
12. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-attributable Disease. A Report of the Surgeon General; Centers for Disease Control and Prevention: Atlanta, GA, USA; 2010.
13. International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monogr. Eval. Carcinog. Risks Hum. 2007, 89, 419-548.
14. Takahashi, H.; Ogata, H.; Nishigaki, R.; Broide, D.H.; Karin, M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta-and JNK1-dependent inflammation. Cancer Cell 2010, 17, 89-97.
15. International Union Against Cancer, 2007. Available online: http://www.deathsfromsmoking.net/ (accessed on 15 November 2013).
16. International Agency for Research on Cancer. Betel-quid and areca-nut chewing and some arece-nut-derived nitrosamines. IARC Monogr. Eval. Carcinog. Risks Hum. 2004, 85, 44-300.
17. Steward, S.L.; Cardinez, C.J.; Richardson, L.C.; Norman, L.; Kaufmann, R.; Pechacek, T.F.; Thompson, T.D.; Weir, H.K.; Sabatino, S.A. Surveillance for cancer associated with tobacco use-United States, 1999-2004. Morbid. Mortal. Wkly. Rep. 2008, 57, 1-33.
18. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. IARC Monogr. Eval. Carcinog. Risks Hum. 2004, 83, 1-1438.
19. Rodgman, A.; Perfetti, T.A. Alphabetical component index. In The Chemical Components of Tobacco and Tobacco Smoke; Rodgman, A., Perfetti, T.A., Eds.; CRC Press: Boca Raton, FL, USA, 2009; pp. 1483-1784.
20. Tutka, P.; Mosiewicz, J.; Wielosz, M. Pharmacokinetics and metabolism of nicotine. Pharmacol. Rev. 2005, 57,143-153.
21. International Agency for Research on Cancer. Tobacco habits other than smoking: Betel quid and Areca nut chewing and some related nitrosamines. IARC Monogr. Eval. Carcinog. Risks Hum. 1985, 37, 37-202.
22. Zu, K.; Giovannucci, E. Smoking and aggressive prostate cancer: A review of the epidemiologic evidence. Cancer Causes Control 2009, 20, 1799-1810.
23. US Department of Health and Human Services. Report on Carcinogens, 12th ed.; US Department of Health and Human Services, Public Health Service, National Toxicology Program: Research Triangle Park, NC, USA, 2011.
24. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke. A Report of the Surgeon General; US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2006.
25. National Cancer Institutes. Health effects of exposure to environmental tobacco smoke. In Smoking and Tobacco Control Monograph; National Cancer Institute: Bethesda, MD, USA, 1999; Volume 10.
26. National Cancer Institute. Cancer Progress Report-2003 Update; National Cancer Institute, NIH, DHHS: Bethesda, MD, USA, 2004.
27. National Cancer Institute. Smokeless Tobacco and Cancer. FactSheet. Available online: http://www.cancer.gov/cancertopics/factsheet/Tobacco/smokeless/ (accessed on 22 March 2014).
28. Hecht, S.S.; Carmella, S.G.; Murphy, S.E.; Riley, W.T.; Le, C.; Luo, X.; Mooney, M.; Hatsukami, D.K. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco user and cigarette smokers. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1567-1567.
29. Henningfield, J.E.; Benowitz, N.L.; Slade, J.; Houston, T.P.; Davis, R.M.; Deitchman, S.D. Reducing the addictiveness of cigarettes. Tob. Control 1998, 7, 281-293.
30. Severson, H.H.; Hatsukami, D. Smokeless tobacco cessation. Prim. Care 1999, 26, 529-551.
31. Hoffmann, D.; Hoffmann, I.; El-Bayoumy, K. The less harmful cigarette: A controversial issue: A tribute to Ernst L. Wynder. Chem. Res. Toxicol. 2001, 14, 767-790.
32. Pfeifer, G.P.; Denissenko, M.F.; Olivier, M.; Tretyakova, N.; Hecht, S.S.; Hainaut, P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21, 7435-7451.
33. Stepanov, I.; Carmella, S.G.; Briggs, A.; Hertsgaard, L.; Lindgren, B.; Hatsukami, D.; Hecht, S.S. Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res. 2009, 69, 8236-8240.
34. Hecht, S.S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 1998, 11, 559-603.
35. Hoffmann, D.; Hecht, S.S. Nicotine-derived N-nitrosamines and tobacco-related cancer: Current status and future directions. Cancer Res. 1985, 45, 935-944.
36. Hecht, S.S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res. 1999, 424, 127-142.
37. Hecht, S.S.; Hoffmann, D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988, 9, 875-884.
38. Hoffmann, D.; Brunnemann, K.D.; Prokopczyk, B.; Djordjevic, M.V. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: Chemistry, biochemistry, carcinogenicity, and relevance to humans. J. Toxicol. Environ. Health 1994, 41, 1-52.
39. Sturla, S.J.; Scott, J.; Lao, Y.; Hecht, S.S.; Villalta, P.W. Mass spectrometric analysis of relative levels of pyridyloxobutylation adducts formed in the reaction of DNA with a chemically activated form of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem. Res. Toxicol. 2005, 18, 1048-1055.
40. Kiyohara, C.; Yoshimasu, K.; Takayama, K.; Nakanishi, Y. EPHX1 polymorphisms and the risk of lung cancer: A HuGE review. Epidemiology 2006, 17, 89-99.
41. Kiyohara, C.; Yoshimasu, K.; Takayama, K.; Nakanishi, Y. NQO1, MPO, and the risk of lung cancer: A HuGE review. Genet. Med. 2005, 7, 463-478.
42. Hecht, S.S.; Carmella, S.G.; Kenney, P.M.; Low, S.H., Arakawa, K.; Yu, M.C. Effects of cruciferous vegetable consumption on urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in Singapore Chinese. Cancer Epidemiol. Biomark. Prev. 2004, 13, 997-1004.
43. Boyland, E.; Roe, F.J.; Gorrod, J.W. Induction of Pulmonary tumors in mice by nitrosonornicotine, a possible constituent of tobacco smoke. Nature 1964, 202, 1126.
44. Murphy, S.E.; Spina, D.A.; Nunes, M.G.; Pullo, D.A. Glucuronidation of 4-((hydroxymethyl) nitrosamino)-1-(3-pyridyl)-1-butanone, a metabolically activated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, by phenobarbital-treated rats. Chem. Res. Toxicol. 1995, 8, 772-779.
45. Peterson, L.A. Formation, repair, and genotoxic properties of bulky DNA adducts formed from tobacco-specific nitrosamines. J. Nucleic. Acids 2010, doi:10.4061/2010/284935.
46. Maser, E.; Richter, E.; Friebertshauser, J. The identification of 11 beta-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Eur. J. Biochem.1996, 238, 484-489.
47. Wong, H.L.; Murphy, S.E.; Hecht, S.S. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. Chem. Res. Toxicol. 2005, 18, 61-79.
48. Murphy, S.E.; Isaac, I.S.; Ding, X.; McIntee, E.J. Specificity of cytochrome P450 2A3-catalyzed alpha-hydroxylation of N′-nitrosonornicotine enantiomers. Drug Metab. Dispos. 2000, 28, 1263-1266.
49. Yuan, J.M.; Knezevich, A.D.; Wang, R.; Gao, Y.T.; Hecht, S.S.; Stepanov, I. Urinary levels of the tobacco-specific carcinogen N'-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011, 32, 1366-1371.
50. Patten, C.J.; Smith, T.J.; Friesen, M.J.; Tynes, R.E.; Yang, C.S.; Murphy, S.E. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes. Carcinogenesis 1997, 18, 1623-1630.
51. Jansen, J.G.; de Groot, A.J.; van Teijlingen, C.M.; Tates, A.D.; Vrieling, H.; van Zeeland, A.A. Induction of hprt gene mutations in splenic T-lymphocytes from the rat exposed in vivo to DNA methylating agents is correlated with formation of O6-methylguanine in bone marrow and not in the spleen. Carcinogenesis 1996, 17, 2183-2191.
52. Margison, G.P.; Santibanez Koref, M.F.; Povey, A.C. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002, 17, 483-487.
53. Povey, A.C.; Badawi, A.F.; Cooper, D. P.; Hall, C.N.; Harrison, K.L.; Jackson, P.E.; Lees, N.P.; O'Connor, P.J.; Margison, G.P. DNA alkylation and repair in the large bowel: Animal and human studies. J. Nutr. 2002, 132, 3518S-3521S.
54. Plosky, B.; Samson, L.; Engelward, B.P.; Gold, B.; Schlaen, B.; Millas, T.; Magnotti, M.; Schor, J.; Scicchitano, D.A. Base excision repair and nucleotide excision repair contribute to the removal of N-methylpurines from active genes. DNA Repair 2002, 1, 683-696.
55. Liu, L.; Castonguay, A.; Gerson, S.L. Lack of correlation between DNA methylation and hepatocarcinogenesis in rats and hamsters treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 1992, 13, 2137-2140.
56. Wang, L.; Spratt, T.E.; Liu, X.K.; Hecht, S.S.; Pegg, A.E.; Peterson, L.A. Pyridyloxobutyl adduct O6-[4-oxo-4-(3-pyridyl)butyl]guanine is present in 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone-treated DNA and is a substrate for O6-alkylguanine-DNA alkyltransferase. Chem. Res. Toxicol. 1997, 10, 562-567.
57. Thomson, N.M.; Kenney, P.M.; Peterson, L.A. The pyridyloxobutyl DNA adduct, O6-[4-oxo-4-(3-pyridyl)butyl]guanine, is detected in tissues from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-treated A/J mice. Chem. Res. Toxicol. 2003, 16, 1-6.
58. Pauly, G.T.; Peterson, L.A.; Moschel, R.C. Mutagenesis by O(6)-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells. Chem. Res. Toxicol. 2002, 15, 165-169.
59. Brown, P.J.; Bedard, L.L.; Massey, T.E. Repair of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA pyridyloxobutylation by nucleotide excision repair. Cancer Lett. 2008, 260, 48-55.
60. Li, L.; Perdigao, J.; Pegg, A.E.; Lao, Y.; Hecht, S.S.; Lindgren, B.R.; Reardon, J.T.; Sancar, A.; Wattenberg, E.V.; Peterson, L.A. The influence of repair pathways on the cytotoxicity and mutagenicity induced by the pyridyloxobutylation pathway of tobacco-specific nitrosamines. Chem. Res. Toxicol. 2009, 22, 1464-1472.
61. Fan, J.; Wilson, D.M. Protein-protein interactions and posttranslational modifications in mammalian base excision repair. Free Radic. Biol. Med. 2005, 38, 1121-1138.
62. Petit, C.; Sancar, A. Nucleotide excision repair: From E. coli to man. Biochimie 1999, 81, 15-25.
63. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73, 39-85.
64. Thompson, L.H.; Brookman, K.W.; Dillehay, L.E.; Mooney, C.L.; Carrano, A.V. Hypersensitivity to mutation and sister-chromatid-exchange induction in CHO cell mutants defective in incising DNA containing UV lesions. Somatic Cell Genet. 1982, 8, 759-573.
65. Hecht, S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91, 1194-1210.
66. Abdel-Rahman, S.Z.; El-Zein, R.A. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett. 2000, 159, 63-71.
67. Affatato, A.A.; Wolfe, K.J.; Lopez, M.S.; Hallberg, C.; Ammenheuser, M.M.; Abdel-Rahman, S.Z. Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ. Mol. Mutagen 2004, 44, 65-73.
68. De Marco, F. Oxidative stress and HPV carcinogenesis. Viruses 2013, 5, 708-731.
69. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121, 2381-2386.
70. Pryor, W.A.; Stone, K.; Zang, L.Y.; Bermudez, E. Fractionation of aqueous cigarette tar extracts: Fractions that contain the tar radical cause DNA damage. Chem. Res. Toxicol. 1998, 11, 441-448.
71. Rosa, J.G.; Prokopczyk, B.; Desai, D.H.; Amin, S.G.; El-Bayoumy, K. Elevated 8-hydroxy-2'-deoxyguanosine levels in lung DNA of A/J mice and F344 rats treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and inhibition by dietary 1,4-phenylene-bis(methylene)selenocyanate. Carcinogenesis 1998, 19, 1783-1788.
72. Chung, F.L.; Xu, Y. Increased 8-oxodeoxyguanosine levels in lung DNA of A/J mice and F344 rats treated with the tobacco-specific nitrosamine 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone. Carcinogenesis 1992, 13, 1269-1272.
73. Bilodeau, J.F.; Wang, M.; Chung, F.L.; Castonguay, A. Effects of nonsteroidal anti-inflammatory drugs on oxidative pathways in A/J mice. Free Radic. Biol. Med. 1995, 18, 47-54.
74. Nishimura, S. Mammalian Ogg1/Mmh gene plays a major role in repair of the 8-hydroxyguanine lesion in DNA. Progr. Nucleic Acid Res. Mol. Biol. 2001, 68, 107-123.
75. Nishimura, S. Involvement of mammalian OGG1(MMH) in excision of the 8-hydroxyguanine residue in DNA. Free Radic Biol. Med. 2002, 32, 813-821.
76. Lee, J.W.; Kim, J.H. Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells. J. Biol. Chem. 2013, 288, 30054-30063.
77. Galzi, J.L.; Revah, F.; Bessis, A.; Changeux, J.P. Functional architecture of the nicotinic acetylcholine receptor: From electric organ to brain. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 37-72.
78. Lindstrom, J. Neuronal nicotinic acetylcholine receptors. Ion Channels 1996, 4, 377-450.
79. Gotti, C.; Fornasari, D.; Clementi, F. Human neuronal nicotinic receptors. Progr. Neurobiol. 1997, 53, 199-237.
80. Singh, S.; Pillai, S.; Chellappan, S. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J. Oncol. 2011, doi: 10.1155/2011/456743.
81. Schuller, H.M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat. Rev. Cancer 2009, 9, 195-205.
82. Schuller, H.M.; Orloff, M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem. Pharmacol. 1998, 55, 1377-1384.
83. Arredondo, J.; Chernyavsky, A.I.; Grando, S.A. Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer Biol. Ther. 2006, 5, 511-517.
84. Plummer, H.K.; Dhar, M.; Schuller, H.M. Expression of the alpha7 nicotinic acetylcholine receptor in human lung cells. Respir. Res. 2005, 6, 29.
85. Sartelet, H.; Maouche, K.; Totobenazara, J.L.; Petit, J.; Burlet, H.; Monteau, M.; Tournier, J.M.; Birembaut, P. Expression of nicotinic receptors in normal and tumoral pulmonary neuroendocrine cells (PNEC). Pathol. Res. Pract. 2008, 204, 891-898.
86. Wessler, I.; Kirkpatrick, C.J. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008, 154, 1558-1571.
87. Arredondo, J.; Chernyavsky, A.I.; Grando, S.A. Overexpression of SLURP-1 and -2 alleviates the tumorigenic action of tobacco-derived nitrosamine on immortalized oral epithelial cells. Biochem. Pharmacol. 2007, 74, 1315-1359.
88. Sheppard, B.J.; Williams, M.; Plummer, H.K.; Schuller, H.M. Activation of voltage-operated Ca2+-channels in human small cell lung carcinoma by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Int. J. Oncol. 2000, 16, 513-518.
89. Jull, B.A.; Plummer, H.K.; Schuller, H.M. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of C-MYC in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J. Cancer Res. Clin. Oncol. 2001, 127, 707-717.
90. Cattaneo, M.G.; Codignola, A.; Vicentini, L.M.; Clementi, F.; Sher, E. Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma. Cancer Res. 1993, 53, 5566-5568.
91. Jin, Z.; Gao, F.; Flagg, T.; Deng, X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and C-MYC through phosphorylation in regulating cell survival and proliferation. J. Biol. Chem. 2004, 279, 40209-40219.
92. US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General; US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2014.
93. Purdue, M.P.; Gold, L.; Jarvholm, B.; Alavanja, M.C.; Ward, M.H.; Vermeulen, R. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax 2007, 62, 51-56.
94. Mannino, D.M. Chronic obstructive pulmonary disease: Definition and epidemiology. Respir. Care 2003, 48, 1185-1191.
95. Gwilt, C.R.; Donnelly, L.E.; Rogers, D.F. The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation? Pharmacol. Ther. 2007, 115, 208-222.
96. Schuller, H.M. Carbon dioxide potentiates the mitogenic effects of nicotine and its carcinogenic derivative, NNK, in normal and neoplastic neuroendocrine lung cells via stimulation of autocrine and protein kinase C-dependent mitogenic pathways. Neurotoxicology 1994, 15, 877-886.
97. Schuller, H.M. Nitrosamines as nicotinic receptor ligands. Life Sci. 2007, 80, 2274-2280.
98. Schuller, H.M. Neurotransmission and cancer: Implications for prevention and therapy. Anticancer Drugs 2008, 19, 655-671.
99. Schuller, H.M.; Tithof, P.K.; Williams, M.; Plummer, H. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 1999, 59, 4510-4515.
100. Schuller, H.M.; Porter, B.; Riechert, A. Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J. Cancer Res. Clin. Oncol. 2000, 126, 624-630.
101. Boswell-Smith, V.; Spina, D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int. J. Chron. Obstruct. Pulmon. Dis. 2007, 2, 121-129.
102. Wang, D.; Cui, X. Evaluation of PDE4 inhibition for COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2006, 1, 373-379.
103. West, K.A.; Brognard, J.; Clark, A.S.; Linnoila, I.R.; Yang, X.; Swain, S.M.; Harris, C.; Belinsky, S.; Dennis, P.A. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Invest. 2003, 111, 81-90.
104. Tsurutani, J.; Castillo, S.S.; Brognard, J.; Granville, C.A.; Zhang, C.; Gills, J.J.; Sayyah, J.; Dennis, P.A. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 2005, 26, 1182-1195.
105. Dasgupta, P.; Kinkade, R.; Joshi, B.; Decook, C.; Haura, E.; Chellappan, S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc. Natl. Acad. Sci. USA 2006, 103, 6332-6337.
106. Dasgupta, P.; Rastogi, S.; Pillai, S.; Ordonez-Ercan, D.; Morris, M.; Haura, E.; Chellappan, S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J. Clin. Invest. 2006, 116, 2208-2217.
107. Arredondo, J.; Chernyavsky, A.I.; Grando, S.A. The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells. J. Cancer Res. Clin. Oncol. 2006, 32, 653-663.
108. Laag, E.; Majidi, M.; Cekanova, M.; Masi, T.; Takahashi, T.; Schuller, H.M. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int. J. Cancer 2006, 119, 1547-1552.
109. Majidi, M.; Al-Wadei, H.A.; Takahashi, T.; Schuller, H.M. Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. Cancer Res. 2007, 67, 6863-6871.
110. Lindstrom, J.; Anand, R.; Gerzanich, V.; Peng, X.; Wang, F.; Wells, G. Structure and function of neuronal nicotinic acetylcholine receptors. Progr. Brain Res. 1996, 109, 125-137.
111. Kawai, H.; Berg, D.K. Nicotinic acetylcholine receptors containing alpha 7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-regulated by chronic nicotine exposure. J. Neurochem. 2001, 78, 1367-1378.
112. Schuller, H.M.; Al-Wadei, H.A.; Majidi, M. Gamma-aminobutyric acid, a potential umor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis 2008, 29, 1979-1985.
113. Nakazawa, K.; Ohno, Y. Block by phytoestrogens of recombinant human neuronal nicotinic receptors. J. Pharmacol. Sci. 2003, 93, 118-121.
114. Xu, L.; Deng, X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu-and m-calpain in association with increased secretion, cell migration, and invasion. J. Biol. Chem. 2004, 279, 53683-53690.
115. Sato, M.; Vaughan, M.B.; Girard, L.; Peyton, M.; Lee, W.; Shames, D.S.; Ramirez, R.D.; Sunaga, N.; Gazdar, A.F.; Shay, J.W. et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006, 66, 2116-2128.